The biotechnology sector often presents investors with companies that combine rapid revenue growth with significant long-term potential. One company that has recently attracted investor attention is TG Therapeutics (NASDAQ: TGTX). Following its strong commercial launch of its multiple sclerosis treatment, the company has experienced rapid revenue expansion and improving profitability. Despite these improvements, the stock price has struggled over the past year, potentially creating an interesting opportunity for long-term investors. In this article we will dive into TG Therapeutics recent earnings, stock performance & valuation, growth potential, and the risks we should consider.
Stockmindsweb
Seeking Undervalued Stocks With Great Future Growth in the US Stock Market